13 Jun Potential Side Effects of Immunotherapy in Head and Neck Cancer
Posted at 21:42h
in Recent Posts
Dan Zandberg, MD Introduction Currently, two immunotherapy medications, Nivolumab (Opdivo) and Pembrolizumab (Keytruda) are approved in the USA for recurrent and or metastatic squamous cell carcinoma of head and neck (HNSCC) after a patient received and failed “platinum” based chemotherapy. Both Nivolumab...